Year: 2025

CHICAGO, March 11, 2025 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its second quarter and first six-months of fiscal year 2025.       Second Quarter Year to Date(in thousands, except per share amounts) Ended January 31, Ended January 31,  2025 2024 Change 2025 2024 ChangeConsolidated Results            Net Sales $ 116,914   $ 105,668     11 % $ 244,859   $ 217,106     13 %Operating Income * $ 17,482   $ 15,165     15 % $ 38,672   $ 28,321     37 %Net Income $ 12,921   $ 12,382     4 % $ 29,297   $ 23,124     27 %EBITDA † $ 22,216   $ 19,233     16 % $ 48,383   $ 36,617     32 %Diluted EPS – Common ‡ $ 0.89   $ 0.85     5 % $ 2.01   $ 1.60     26 %Business to Business            Net Sales $ 43,416   $ 36,234     20 % $ 91,831   $ 75,395     22 %Segment...

Delivers Fourth Quarter Results in Line with and Above Guidance Ranges Provides 2025 Guidance SAN FRANCISCO, March 11, 2025 (GLOBE NEWSWIRE) — Allbirds, Inc. (NASDAQ: BIRD), a global lifestyle brand that innovates with sustainable materials to make better products in a better way, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 OverviewFourth quarter net revenue decreased 22.4% to $55.9 million versus a year ago, within the Company’s guidance range. Full year net revenue decreased 25.3% to $189.8 million versus a year ago. Fourth quarter gross margin declined approximately 670 basis points to 31.3% versus a year ago; full year gross margin improved approximately 170 basis points to 42.7% versus a year ago. Fourth quarter net loss of $25.7 million,...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended Dec. 31, 2024. “2024 was a transformational year for Zevra. We emerged as a commercial stage company and are executing on the opportunity to positively impact the lives of people living with rare diseases,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “We are...

– Total net sales of $145.4 million versus $147.2 million in prior year fourth quarter –– Net income of $2.1 million versus $3.6 million in prior year fourth quarter –– EBITDA of $7.3 million versus $9.9 million in prior year fourth quarter –– Board of Directors approves additional stock repurchase plan –– Provides full-year outlook – ST. PETERSBURG, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its fourth quarter 2024 results. “For 2024, we grew sales and diluted EPS 4% and 35%, respectively, while strengthening our balance sheet and making strategic investments in our people, services, products and technology.  Capping the year, our fourth quarter results came in as expected, placing us within our full-year outlook ranges which were...

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the American Society of Hematology 2024 Annual Meeting Acceleration of development of IMPT-314 in LBCL; remain on track to initiate a pivotal trial in the 3rd line and later setting in mid-2025 and expect to initiate a pivotal trial in the 2nd line setting by early 2026 Advancing next-generation CAR T-cell product candidates with new targets and technologies; first IND for fully‑armed solid tumor product candidate expected in 2026 Cash, cash equivalents and marketable...

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year HighlightsTotal revenue of $8.7 million in the fourth quarter of 2024, a decrease of 45% over the fourth quarter of 2023. The decrease in total revenue was due to multiple one-time approval milestones in the fourth quarter of 2023. Core business revenue of $8.6 million in the fourth quarter of 2024, an increase of 20% over the fourth quarter of 2023. Strategic Platform License (SPL) Program-related revenue...

Increased Product Sales to $133 Million in 2024 Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024 Corporate Update Conference Call Today at 4:30 PM ETNEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2024. “2024 was a year of strong financial performance and operational execution for SIGA in which we delivered $133 million in product sales and $70 million of pre-tax operating income. These results mark the second consecutive year of product revenue growth, reflecting SIGA’s continued financial strength,” stated Diem Nguyen, Chief Executive Officer. “As we enter 2025, we remain focused on durable growth and...

LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) — Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine” and/or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago QuarterNet sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency). GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share. Adjusted EBITDA up 6% to $10.3 million compared to $9.7 million.Full Year 2024 Financial Summary vs. 2023Net sales were up 2.0% to $454.4 million compared to $445.3 million (up 3.8% in constant currency). GAAP...

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...